drugset / Trial / NCT02048787
Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.
Non-randomizedParallel-groupOpen-labelBasic science
Summary
To characterize the pharmacokinetics and safety of buparlisib following a single 50 mg oral dose in subjects with moderate and severe renal impairment.
Timeline
- Start
- 2014-03
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buparlisib | Small molecule | 50 mg | Oral |